0001193125-26-059551.txt : 20260219 0001193125-26-059551.hdr.sgml : 20260219 20260219163820 ACCESSION NUMBER: 0001193125-26-059551 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20260219 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260219 DATE AS OF CHANGE: 20260219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 26655094 BUSINESS ADDRESS: STREET 1: 101 REDWOOD SHORES PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 101 REDWOOD SHORES PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 8-K 1 d25779d8k.htm 8-K 8-K
CORCEPT THERAPEUTICS INC false 0001088856 0001088856 2026-02-19 2026-02-19
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

February 19, 2026

Date of Report (date of earliest event reported)

 

 

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-50679   77-0487658
(State or other jurisdiction
of incorporation)		  

(Commission

File Number)

   (I.R.S. Employer
Identification No.)

101 Redwood Shores Parkway, Redwood City, CA 94065

(Address of Principal Executive Offices) (Zip Code)

(650) 327-3270

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.001 par value   CORT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 8.01.

Other Events.

On February 19, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does not infringe two of the Company’s patents concerning methods of safely co-administering Korlym and drugs that inhibit the CYP3A4 enzyme, including drugs that are commonly prescribed to patients with Cushing’s syndrome. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits

 

Exhibits
No.

   

Description

 99.1    Press Release of Corcept Therapeutics Incorporated, February 19, 2026.
104.1    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CORCEPT THERAPEUTICS INCORPORATED
Date: February 19, 2026     By:  

/s/ Atabak Mokari

    Name:   Atabak Mokari
    Title:   Chief Financial Officer
 EX-99.1 2 d25779dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO      

CONTACT:

Investor inquiries:

ir@corcept.com

Media inquiries:

communications@corcept.com

www.corcept.com

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

REDWOOD CITY, Calif., (February 19, 2026) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does not infringe two of Corcept’s patents concerning methods of safely co-administering Korlym and drugs that inhibit the CYP3A4 enzyme, including drugs that are commonly prescribed to patients with Cushing’s syndrome. The ruling affirms a December 2023 verdict by the Federal District Court for the District of New Jersey.

“We are disappointed in the Court’s ruling,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “The patents we asserted in this case cover methods of safely treating patients with Cushing’s syndrome that physicians rely on every day. We will vigorously defend our rights and are currently considering the best way to pursue judicial review of this decision.”

About Corcept Therapeutics

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com.

Forward-Looking Statements

Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC’s website. Forward-looking statements in this press release include, but are not limited to, those related to our intent to defend our intellectual property rights and our consideration of the best way to pursue judicial review of this decision. We disclaim any intention or duty to update forward-looking statements made in this press release.

EX-101.SCH 3 cort-20260219.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cort-20260219_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cort-20260219_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g25779dsp4a.jpg GRAPHIC begin 644 g25779dsp4a.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.25.4
Document and Entity Information
Feb. 19, 2026
Cover [Abstract]  
Entity Registrant Name CORCEPT THERAPEUTICS INC
Amendment Flag false
Entity Central Index Key 0001088856
Document Type 8-K
Document Period End Date Feb. 19, 2026
Entity Incorporation State Country Code DE
Entity File Number 000-50679
Entity Tax Identification Number 77-0487658
Entity Address, Address Line One 101 Redwood Shores Parkway
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code (650)
Local Phone Number 327-3270
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol CORT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports cort-20260219.xsd cort-20260219_lab.xml cort-20260219_pre.xml d25779d8k.htm http://xbrl.sec.gov/dei/2025 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d25779d8k.htm": { "nsprefix": "cort", "nsuri": "http://www.corcept.com/20260219", "dts": { "schema": { "local": [ "cort-20260219.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd" ] }, "labelLink": { "local": [ "cort-20260219_lab.xml" ] }, "presentationLink": { "local": [ "cort-20260219_pre.xml" ] }, "inline": { "local": [ "d25779d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2025": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 22 }, "report": { "R1": { "role": "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2026-02-19_to_2026-02-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d25779d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2026-02-19_to_2026-02-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d25779d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://www.corcept.com//20260219/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001193125-26-059551-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-26-059551-xbrl.zip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end XML 17 d25779d8k_htm.xml IDEA: XBRL DOCUMENT 0001088856 2026-02-19 2026-02-19 CORCEPT THERAPEUTICS INC false 0001088856 8-K 2026-02-19 DE 000-50679 77-0487658 101 Redwood Shores Parkway Redwood City CA 94065 (650) 327-3270 false false false false Common Stock, $0.001 par value CORT NASDAQ false